Canaccord Genuity Group assumed coverage on shares of Omada Health (NASDAQ:OMDA – Free Report) in a research note released on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $27.00 price objective on the stock.
Separately, Wall Street Zen upgraded Omada Health to a “hold” rating in a research note on Monday, June 16th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Omada Health has a consensus rating of “Moderate Buy” and a consensus target price of $23.57.
Read Our Latest Report on OMDA
Omada Health Price Performance
About Omada Health
Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.
Featured Stories
- Five stocks we like better than Omada Health
- What Are Dividend Champions? How to Invest in the Champions
- Rigetti Computing: Cantor’s Bullish Call May Be Just the Start
- Compound Interest and Why It Matters When Investing
- Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead
- What is Put Option Volume?
- 3 Top Stocks Under $20 Riding the “Made in America” Wave
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
